Free Trial

Amryt Pharma (AMYT) News Today

Notice: This company has been marked as potentially delisted and may not be actively trading.
Alembic Pharmaceuticals Ltd.
AMYT Historical Data
Clear Harbor Asset Management LLC Sells 13,573 Shares of Amryt Pharma plc (NASDAQ:AMYT)
Clear Harbor Asset Management LLC lowered its holdings in shares of Amryt Pharma plc (NASDAQ:AMYT - Get Rating) by 15.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,843 shares of the company's stock
Amryt Pharma Stock (NASDAQ:AMYT), Dividends
Amryt Pharma plc (NASDAQ:AMYT) Sees Significant Decline in Short Interest
Amryt Pharma plc (NASDAQ:AMYT - Get Rating) saw a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 52,600 shares, a drop of 6.9% from the January 31st total of 56,500 shares. Based on an average daily trading volume, of 570,900 shares, the short-interest ratio is currently 0.1 days.
Armistice Capital LLC Purchases 94,000 Shares of Amryt Pharma plc (NASDAQ:AMYT)
Armistice Capital LLC lifted its position in shares of Amryt Pharma plc (NASDAQ:AMYT - Get Rating) by 8.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,272,000 shares of the company's stock after pu
Amryt Pharma Sees Unusually High Options Volume (NASDAQ:AMYT)
Amryt Pharma plc (NASDAQ:AMYT - Get Rating) was the recipient of unusually large options trading activity on Friday. Stock investors acquired 6,003 put options on the stock. This is an increase of 1,596% compared to the average volume of 354 put options.
Amryt Pharma (NASDAQ:AMYT) Receives Hold Rating from Canaccord Genuity Group
Canaccord Genuity Group restated a "hold" rating and issued a $17.00 price objective (down from $19.00) on shares of Amryt Pharma in a research note on Tuesday.
Amryt Pharma's (AMYT) "Market Perform" Rating Reaffirmed at SVB Leerink
SVB Leerink reiterated a "market perform" rating and set a $14.50 price target (down previously from $19.00) on shares of Amryt Pharma in a report on Monday.
Maxim Group Reaffirms Their Buy Rating on Amryt Pharma (AMYT)
Amryt Pharma plc (NASDAQ:AMYT) Sees Significant Decrease in Short Interest
Amryt Pharma plc (NASDAQ:AMYT - Get Rating) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 68,700 shares, a decrease of 22.0% from the November 15th total of 88,100 shares. Based on an average trading volume of 35,300 shares, the short-interest ratio is presently 1.9 days.
Amryt Pharma plc (NASDAQ:AMYT) Sees Significant Growth in Short Interest
Amryt Pharma plc (NASDAQ:AMYT - Get Rating) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 103,900 shares, a growth of 19.6% from the October 15th total of 86,900 shares. Based on an average daily trading volume, of 30,400 shares, the short-interest ratio is currently 3.4 days.
SVB Securities Keeps Their Buy Rating on Amryt Pharma (AMYT)
Amryt Reports Q3 2022 Financial and Operational Results
Q3 2022 EPS Estimates for Amryt Pharma plc Reduced by SVB Leerink (NASDAQ:AMYT)
Amryt Pharma plc (NASDAQ:AMYT - Get Rating) - Equities research analysts at SVB Leerink cut their Q3 2022 earnings per share estimates for shares of Amryt Pharma in a report released on Monday, October 24th. SVB Leerink analyst M. Foroohar now anticipates that the company will earn ($0.02) per sh
Amryt Pharma (AMYT) Set to Announce Quarterly Earnings on Thursday
Amryt Pharma (NASDAQ:AMYT) will be releasing earnings before the market opens on Thursday, November 3, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=481867)
Amryt Supports Global EB Awareness Week 2022
Amryt to Report Q3 2022 Results on November 3, 2022
Short Interest in Amryt Pharma plc (NASDAQ:AMYT) Rises By 17.0%
Amryt Pharma plc (NASDAQ:AMYT - Get Rating) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 89,500 shares, an increase of 17.0% from the September 15th total of 76,500 shares. Based on an average daily trading volume, of 42,600 shares, the short-interest ratio is currently 2.1 days.
Short Interest in Amryt Pharma plc (NASDAQ:AMYT) Decreases By 16.9%
Amryt Pharma plc (NASDAQ:AMYT - Get Rating) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totalling 76,500 shares, a decrease of 16.9% from the August 31st total of 92,100 shares. Based on an average daily volume of 56,700 shares, the short-interest ratio is currently 1.3 days.
Amryt Supports FH Awareness Day – September 24, 2022
Amryt Pharma's (AMYT) Buy Rating Reiterated at Canaccord Genuity Group
Canaccord Genuity Group reaffirmed a "buy" rating and issued a $19.00 price target on shares of Amryt Pharma in a research note on Tuesday.
Amryt Pharma (NASDAQ:AMYT) Rating Reiterated by HC Wainwright
HC Wainwright reissued a "buy" rating on shares of Amryt Pharma in a research report on Monday.
Amryt Reports Record Q2 2022 Results
Short Interest in Amryt Pharma plc (NASDAQ:AMYT) Increases By 24.6%
Amryt Pharma plc (NASDAQ:AMYT - Get Rating) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 102,700 shares, a growth of 24.6% from the June 30th total of 82,400 shares. Based on an average daily volume of 84,200 shares, the short-interest ratio is currently 1.2 days.
Amryt to Report Q2 2022 Results on August 4, 2022
Get Amryt Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter.

Former Hedge Fund Manager Issues Crash Prediction (Ad)

Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.

Get our No. 1 stock (with 500%-plus upside potential) for this rare market event now.

AMYT Media Mentions By Week

AMYT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AMYT
News Sentiment

0.00

0.74

Average
Medical
News Sentiment

AMYT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AMYT Articles
This Week

0

0

AMYT Articles
Average Week

Get Amryt Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:AMYT) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners